Navigation Links
MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Date:3/1/2011

e acute treatment of migraine, upon potential FDA approval.  Allergan will leverage its existing U.S. sales force dedicated to headache specialists using BOTOX® for Chronic Migraine, which will be complemented by a MAP Pharmaceuticals field sales force targeting neurologists and pain specialists. The Company will retain all rights to commercialize LEVADEX to primary care physicians within the United States, as well as to physicians outside the United States.
  • Received $60.0 million in February 2011 pursuant to the collaboration agreement with Allergan, and may receive up to $97.0 million in additional payments upon meeting certain regulatory milestones associated with the initial indication.
  • Raised gross proceeds of $20.0 million in January 2010 through our equity line of credit.
  • Raised gross proceeds of $50.0 million in October 2010 in a common stock offering.

    • Fourth Quarter and 2010 Year End Financial ResultsRevenues for the quarter and year ended December 31, 2010 were $0.0 for both periods, compared to $2.8 million and $54.2 million, respectively, for the same periods in 2009. Revenues for the quarter and year ended December 31, 2009 were due to amortization of an upfront payment and reimbursements for development expenses related to Unit Dose Budesonide (UDB), pursuant to a previous license agreement with AstraZeneca.

    Research and development (R&D) expenses for the fourth quarter ended December 31, 2010 were $9.7 million, compared to $12.4 million for the same period in 2009.  The decrease in R&D expenses was driven primarily by a decrease in clinical and other related expenses to support the LEVADEX Phase 3 clinical program and a decrease in clinical and other related expenses to support the UDB Phase 3 clinical program which was suspended in the third quarter of 2009, partially offset by an increase in personnel related expenses, including stock-based compensation.

    R&D expenses
    '/>"/>

    SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
    2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
    3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
    4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
    5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
    6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
    7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
    8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
    9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
    10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
    11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... Topricin Pain Relief and Healing ... listed among nationally recommended over-the-counter (OTC) health products ... "U.S. News" Health in collaboration with "Pharmacy Times." ... 1 Pharmacists Recommended designation” in the “Topical Analgesics” ... and is the only homeopathic formula to earn ...
    (Date:5/17/2013)... Elsevier, a world-leading provider of scientific, technical and medical ... a recent study in Reproductive BioMedicine Online ... those with an abnormal chromosomal composition can be identified ... blastocysts, thereby classifying the risk of genetic abnormality without ... has undertaken a retrospective study, using their predictive model ...
    (Date:5/17/2013)...  Yongye International, Inc. (NASDAQ: YONG ) ... distributor of crop nutrient products in the ... on May 16, 2013, the special committee (the "Special ... Directors") was provided a letter (the "Letter") issued by ... Limited ("Abax") to Full Alliance International Limited ("Full Alliance"). ...
    (Date:5/17/2013)... Frederick, MD (PRWEB) May 17, 2013 ... release of ezColony version 4.1, a versatile refinement ... world-class premier software solution, improves its advanced methodical ... animal facilities with ezColony 4.1. The network-based platform ... to conduct effective research. While continuing to emphasize ...
    Breaking Biology Technology:Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Breakthrough for IVF? 2Breakthrough for IVF? 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
    ... 24, 2011 Zeltia Group,s net revenues totaled 153.5 ... percent more than in 2009 (123.4 million euro, or ... to a 70 percent increase in Yondelis® sales. ... 79.4 million euro (approximately 109.3 million USD) in 2010 ...
    ... Reportlinker.com announces that a new market research ... Propylene Oxide: 2010 World Market Outlook And ... The report analyzes worldwide markets for Propylene ... America. It provides the most complete and current ...
    ... PITTSBURGH, Feb. 24, 2011 Mylan Inc. (Nasdaq: MYL ... months ended December 31, 2010, and provided its financial guidance for ... diluted EPS of $0.45 for the quarter ended December 31, 2010 ... of 36%; Adjusted diluted EPS of $1.61 for the ...
    Cached Biology Technology:74 Percent EBITDA Improvement at Zeltia Group in 2010 2Reportlinker Adds Propylene Oxide: 2010 World Market Outlook and Forecast 2Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 2Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 3Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 4Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 5Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 6Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 7Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 8Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 9Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 10Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 11Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 12Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 13Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 14Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 15Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 16Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 17Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 18
    (Date:5/20/2013)... A National Science Foundation (NSF) planning grant will help ... a joint program of the University of Illinois at ... , "CARD will be devoted to research in drying ... products; forestry and paper products; chemical products; textiles; and ... of food science and human nutrition and the Illinois ...
    (Date:5/20/2013)... (May 20, 2013) - A novel vaccine ... the groundbreaking research that will be unveiled at the ... (NBC). The meeting takes place Monday, May 20 - ... and Marina. , "The main goal of a ... against a pathogen that causes the disease", explained Dr. ...
    (Date:5/20/2013)... at the University of Bristol and published online today ... light on how the brain and inner ear developed ... of Earth Sciences, together with Tom Hbner from the ... 150 million year old dinosaurs. , The two palaeontologists ... lettowvorbecki : a very young (juvenile) individual of ...
    Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2Germ-fighting vaccine system makes great strides in delivery 2Fossil brain teaser 2
    ... relocation of an Inuit village already underway, some 400 ... in Alaska for a UN-affiliated conference April 20-24 to ... to both mitigate and adapt to climate change. ... Global Summit on Climate Change is also designed to ...
    ... U.S. Southwest grew warmer from 18,700 to 10,000 years ago, ... robbing packrats of their favorite food. Now, University of Utah ... the rodents eat toxic creosote bushes that replaced juniper. ... Professor Denise Dearing, senior author of the study, published online ...
    ... news about pancreatic cancer, one of the most fatal ... the lack of effective therapies: Johns Hopkins University pathologist ... aberrantly active in approximately a third of the 250 ... a presentation April 18, at Experimental Biology 2009 in ...
    Cached Biology News:Indigenous peoples at world summit to share climate change observations, coping techniques 2Indigenous peoples at world summit to share climate change observations, coping techniques 3Indigenous peoples at world summit to share climate change observations, coping techniques 4Indigenous peoples at world summit to share climate change observations, coping techniques 5Indigenous peoples at world summit to share climate change observations, coping techniques 6Poison: It's what's for dinner 2Poison: It's what's for dinner 3Poison: It's what's for dinner 4Poison: It's what's for dinner 5Newly discovered epidermal growth factor receptor active in human pancreatic cancers 2
    Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
    MAb to HSV-2, gG-2 HSV-2 Glycoprotein G-2...
    Immunogen for A300-655A was a phosphorylated synthetic peptide, which represented a portion of human RNA Polymerase II (GeneID 5430) around serine 5 of the C-terminal repeat YSPTSPS....
    human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
    Biology Products: